Recent Updates
Recently added Catalysts
ALLR Negative Sentiment Score: 30/100

Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion

Key Takeaway: Allarity Therapeutics, Inc. is facing a class action lawsuit filed by the Portnoy Law Firm on behalf of investors who purchased securities between May 17, 2022, and July 19, 2024. The lawsuit alleges that the company issued materially false statements regarding its business operations and compliance, particularly related to the Dovitinib NDA. This misconduct reportedly led to increased risk of regulatory scrutiny and enforcement actions. Investors have until November 12, 2024, to file a motion to be named lead plaintiff.

Market Sentiment Analysis

CONCERNS & RISKS

  • Allarity Therapeutics is facing a class action lawsuit due to false and misleading statements.
  • The complaint alleges that the company engaged in improper conduct related to its Dovitinib NDA.
  • Allarity's public statements were deemed materially false, exposing them to legal and regulatory risks.
  • Investors have a deadline of November 12, 2024, to file a lead plaintiff motion.

Full Press Release Details

LOS ANGELES, Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR) investors of a class action representing investors that bought securities between May 17, 2022, and July 19, 2024, inclusive (the "Class Period"). Allarity investors have until November 12, 2024 to file a lead plaintiff motion.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The Complaint asserts that, throughout the Class Period, the Defendants issued materially false and misleading statements concerning the Company’s business practices, operations, and adherence to compliance policies. Specifically, it contends that the Defendants inflated the ongoing regulatory prospects of the Dovitinib NDA and engaged in illegal, illicit, or otherwise improper conduct related to the Dovitinib NDA and/or the Dovitinib-DRP PMA, involving Allarity and three of its former officers. This misconduct exposed the Company to heightened risks of regulatory and governmental scrutiny, enforcement actions, and significant legal, financial, and reputational damages. Following the disclosure that Allarity was under investigation for wrongdoing related to the Dovitinib NDA and/or Dovitinib-DRP PMA, the Company downplayed the likelihood of an enforcement action resulting from the investigation. As a result, the Company’s public statements were materially false and misleading throughout the relevant period.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Frequently Asked Questions

What is the class action against Allarity Therapeutics about?

The class action involves investors who purchased Allarity securities between May 17, 2022, and July 19, 2024, alleging false statements about the company's practices.

When is the deadline to file a lead plaintiff motion?

Investors have until November 12, 2024, to file a lead plaintiff motion.

Who can investors contact for legal rights information?

Investors can contact attorney Lesley F. Portnoy at 310-692-8883 or via email.

What claims can investors pursue against Allarity?

Investors can pursue claims related to false statements and regulatory mismanagement concerning Dovitinib.

What is the financial background of Portnoy Law Firm?

The Portnoy Law Firm has recovered over $5.5 billion for investors affected by corporate wrongdoing.

Last updated: Dec 6, 2024